Hydrocortisone sodium succinate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for hydrocortisone sodium succinate and what is the scope of freedom to operate?
Hydrocortisone sodium succinate
is the generic ingredient in three branded drugs marketed by Abbott, Hospira, Abraxis Pharm, Apotex, Baxter Hlthcare, Cipla, Intl Medication, Watson Labs, Zydus Pharms, and Pharmacia And Upjohn, and is included in twenty-eight NDAs. Additional information is available in the individual branded drug profile pages.There is one drug master file entry for hydrocortisone sodium succinate. Eight suppliers are listed for this compound.
Summary for hydrocortisone sodium succinate
| US Patents: | 0 |
| Tradenames: | 3 |
| Applicants: | 10 |
| NDAs: | 28 |
| Drug Master File Entries: | 1 |
| Finished Product Suppliers / Packagers: | 8 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 29 |
| Patent Applications: | 2,720 |
| What excipients (inactive ingredients) are in hydrocortisone sodium succinate? | hydrocortisone sodium succinate excipients list |
| DailyMed Link: | hydrocortisone sodium succinate at DailyMed |
Recent Clinical Trials for hydrocortisone sodium succinate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Second Affiliated Hospital of Wenzhou Medical University | PHASE1 |
| Children's Oncology Group | PHASE1 |
| National Cancer Institute (NCI) | PHASE1 |
Pharmacology for hydrocortisone sodium succinate
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for hydrocortisone sodium succinate
US Patents and Regulatory Information for hydrocortisone sodium succinate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacia And Upjohn | SOLU-CORTEF | hydrocortisone sodium succinate | INJECTABLE;INJECTION | 009866-002 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Watson Labs | HYDROCORTISONE SODIUM SUCCINATE | hydrocortisone sodium succinate | INJECTABLE;INJECTION | 084737-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Intl Medication | HYDROCORTISONE SODIUM SUCCINATE | hydrocortisone sodium succinate | INJECTABLE;INJECTION | 087532-001 | Mar 19, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch